Verismo Therapeutics

HQ
Philadelphia
27 Total Employees
Year Founded: 2020
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.

Verismo Therapeutics Offices

OnSite Workspace

Employees work from physical offices.

Typical time on-site: None
HQPhiladelphia, Pennsylvania, USA